New clinical study to advance development of treatments for liver cirrhosis
The £30m ADVANCE study is the most extensive study into liver disease worldwide
Read More
Tag: Accelerating Discovery: Actionable NASH Cirrhosis Endpoints
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
- Corcept Therapeutics’ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer
- ErVimmune raises 17m euros in funding to develop cancer vaccine
- Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
